NIH Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin Plus Remdesivir to Treat COVID-19 Begins | NIH: National Institute of Allergy and Infectious Diseases

NIH Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin Plus Remdesivir to Treat COVID-19 Begins | NIH: National Institute of Allergy and Infectious Diseases

Wednesday, October 7, 2020 NIAID Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin Plus Remdesivir to Treat COVID-19 Begins Transmission electron micrograph of SARS-CoV-2 virus particles isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID Today NIAID launched a new Phase 3 clinical trial in patients hospitalized with COVID-19 to determine if anti-coronavirus hIVIG―a highly concentrated solution of antibodies that neutralize SARS-CoV-2―combined with remdesivir can boost the immune system to suppress the virus before disease advances. The investigators hypothesize that giving people anti-coronavirus hIVIG at the onset of COVID-19 symptoms, before the body makes a protective immune response on its own, could augment the natural antibody response to SARS-CoV-2, thereby reducing the risk of more serious illness and death. Sponsored and funded by NIAID, the trial is called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.